文献速递银屑病与炎症性皮肤病

古塞奇尤单抗每16周与每8周给药在银屑病超级应答者中的非劣效性维持:GUIDE随机临床试验

Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial.
PubMed 文献 · JAMA Dermatol · 2024-01-01

GUIDE试验第2部分在822例中重度斑块状银屑病患者中比较超级应答者(W20和W28均达PASI 0)接受古塞奇尤单抗每16周与每8周给药的疗效。结果显示每16周组91.9%和每8周组92.6%的患者在W68维持PASI<3,达到10%界值的非劣效性(P=.001)。免疫学指标两组均持续降低,安全性良好。

要点

  • 超级应答者延长古塞奇尤单抗至每16周给药可非劣效维持疾病控制。
  • W68时每16周组91.9%、每8周组92.6%的患者维持PASI<3。
  • 两组皮肤CD8+ TRM细胞计数及血清IL-17A、IL-17F、IL-22、BD-2均持续降低。

核心结论

  • 在W20和W28连续两次达PASI 0的超级应答者中,古塞奇尤单抗每16周给药对维持疾病控制的疗效非劣效于每8周给药。

研究设计与样本

  • GUIDE为正在进行的3b期随机双盲试验,在德国和法国80个中心开展,包含3个部分。
  • 本文报告第2部分,纳入822例接受古塞奇尤单抗治疗的中重度斑块状银屑病患者,其中297例(36.1%)为超级应答者并随机分配至每8周(n=148)或每16周(n=149)给药。

主要发现

  • W68时每16周组91.9%(137/149;90% CI,87.3%-95.3%)和每8周组92.6%(137/148;90% CI,88.0%-95.8%)的超级应答者维持PASI<3,非劣效性检验P=.001。
  • 皮肤CD8阳性组织驻留记忆T细胞计数自基线快速下降并在两组中持续保持低水平。
  • 血清IL-17A、IL-17F、IL-22和β防御素2水平自基线显著下降,并在两组中持续保持低水平至W68。
  • 古塞奇尤单抗耐受性良好,未发现新的安全性信号。

关键数值与推荐

  • 非劣效性界值为10%,主要终点为W68时维持PASI<3的超级应答者比例。

临床怎么用

  • 对于在W20和W28连续两次达到PASI 0的超级应答者,可考虑将古塞奇尤单抗给药间隔延长至每16周以维持疾病控制。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Psoriasis is a chronic inflammatory skin disease with unmet needs for tailored treatment and therapy de-escalation strategies. OBJECTIVE: To evaluate early intervention with and prolonging the dosing interval for guselkumab, a p19 subunit-targeted interleukin (IL)-23 inhibitor, in patients with moderate to severe psoriasis. DESIGN, SETTING, AND PARTICIPANTS: The GUIDE clinical trial is an ongoing phase 3b, randomized, double-blinded trial conducted across 80 centers in Germany and France comprising 3 parts evaluating the impact of early disease intervention, prolonged dosing interval, and maintenance of response following treatment withdrawal among adults with moderate to severe plaque psoriasis. In study part 2, reported herein, first and last patient visits were September 2019 and March 2022, respectively. INTERVENTIONS: In GUIDE part 1 (week [W]0-W28), patients received guselkumab, 100 mg, at W0, W4, W12, and W20. Those achieving a Psoriasis Area and Severity Index (PASI) of 0 at both W20 and W28 were termed super responders (SRes). In part 2 (W28-W68), SRes were randomized to guselkumab, 100 mg, every 8 weeks or every 16 weeks; non-SRes continued open-label guselkumab every 8 weeks. MAIN OUTCOMES AND MEASURES: Primary objective was to demonstrate noninferiority (with a 10% margin) of guselkumab every 16 weeks vs every 8 weeks dosing among SRes for maintenance of disease control (PASI <3 at W68). Biomarker substudies assessed immunologic effects in skin and blood. RESULTS: Overall, 822 patients received guselkumab in part 2 (297 [36.1%] SRes [every 8 weeks/every 16 weeks; n = 148/n = 149] and 525 [63.9%] non-SRes). Among SRes, mean (SD) age was 39.4 (14.1) years, 95 (32.0%) were female, and 202 (68.0%) were male. The primary end point of noninferiority for guselkumab every 16 weeks vs every 8 weeks in SRes was met (P = .001), with 91.9% (137/149; 90% CI, 87.3%-95.3%) of SRes receiving every 16 weeks and 92.6% (137/148; 90% CI, 88.0%-95.8%) of SRes receiving dosing every 8 weeks having PASI lower than 3 at W68. Clinical effects corresponded with immunologic changes; skin CD8-positive tissue-resident memory T (TRM)-cell count decreased quickly from baseline, remaining low in both dosing groups. Similarly, serum IL-17A, IL-17F, IL-22, and β defensin (BD)-2 levels decreased significantly from baseline, remaining low in both dosing groups to W68. Guselkumab was well-tolerated; no new safety signals were identified. CONCLUSIONS AND RELEVANCE: Psoriasis treatment guidelines lack or provide inconsistent advice on patient stratification and treatment de-escalation. We present the first randomized trial providing evidence that, in patients with early complete skin clearance at 2 consecutive visits (W20 and W28), extending the guselkumab dosing interval may control disease activity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03818035.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Eyerich K, Asadullah K, Pinter A, et al. Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial. JAMA Dermatol. 2024. PMID: 39083288. doi:10.1001/jamadermatol.2024.2463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。